# EDGAR Filing Document

**Accession Number:** 0001872812
**File Stem:** 0000000000-23-001601
**Filing Date:** 2023-2
**Character Count:** 3945
**Document Hash:** ac623b7a176235f2c8b338ec9213e95e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001601.hdr.sgml**: 20230425

**ACCESSION NUMBER**: 0000000000-23-001601

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230216

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TC BioPharm (Holdings) plc
- **CENTRAL INDEX KEY:** 0001872812
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR
- **BUSINESS PHONE:** 01414337557

**MAIL ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm (Holdings) Ltd
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm Ltd
- **DATE OF NAME CHANGE:** 20210714
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-23-004152

## Text-Extract

```

United States securities and exchange commission logo

                             February 16, 2023

       Bryan Kobel
       Chief Executive Officer
       TC BioPharm (Holdings) plc
       Maxim 1, 2 Parklands Way
       Holytown, Motherwell, ML1 4WR
       Scotland, United Kingdom

                                                        Re: TC BioPharm
(Holdings) plc
                                                            Draft Registration
Statement on Form F-1
                                                            Submitted February
10, 2023
                                                            CIK No. 0001872812

       Dear Bryan Kobel:

                                                        This is to advise you
that we do not intend to review your registration statement.

               We request that you publicly file your registration statement no
later than 48 hours prior
       to the requested effective date and time. Please refer to Rules 460 and
461 regarding requests for
       acceleration. We remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
       absence of action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.

                             Sincerely,

                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Richard A. Friedman,
Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 16, 2023

Bryan Kobel
Chief Executive Officer
TC BioPharm (Holdings) plc
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom

Re: TC BioPharm (Holdings) plc
Draft Registration Statement on Form F-1
Submitted February 10, 2023
CIK No. 0001872812

Dear Bryan Kobel:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Richard A. Friedman, Esq.